中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Association between mitochondria and hepatocellular injury

DOI: 10.3969/j.issn.1001-5256.2020.03.048
Research funding:

 

  • Received Date: 2019-11-29
  • Published Date: 2020-03-20
  • The mitochondria in liver tissue not only provides energy for substance metabolism in hepatocytes,but also participates in hepatocellular injury and even apoptosis. It also plays an important role in several pathological processes closely associated with hepatocellular injury and apoptosis,such as hepatitis,hepatic fibrosis,precancerous lesion,and liver cancer. This article elaborates on the association between mitochondria and hepatocellular injury from the following aspects: the important role of the change in mitochondrial membrane permeability in hepatocellular injury,hepatocellular injury accelerated by ATP synthesis disorder and consumption,and the association of abnormal Ca2+ homeostasis in hepatocellular mitochondria with hepatocellular injury,in order to provide a theoretical basis for mitochondria-targeted prevention and treatment of chronic liver diseases due to hepatocellular injury.

     

  • [1] MARUF AA,O'BRIEN PJ,NASERZADEH P,et al. Methotrexate induced mitochondrial injury and cytochrome c release in rat liver hepatocytes[J]. Drug Chem Toxicol,2017,41(1):1-11.
    [2] MNATSAKANYAN N,BEUTNER G,PORTER GA,et al. Physiological roles of the mitochondrial permeability transition pore[J]. J Bioenerg Biomembr,2017,49(1):13-25.
    [3] BEUTNER G,ALAVIAN K N,JONAS EA,et al. The mitochondrial permeability transition pore and ATP synthase[J]. Handb Exp Pharmacol,2017,240:21-46.
    [4]ŠILEIKYTE J,FORTE M. The mitochondrial permeability transition in mitochondrial disorders[J]. Oxid Med Cell Longev,2019,2019:3403075.
    [5] HE J,FORD H C,CARROLL J,et al. Persistence of the mitochondrial permeability transition in the absence of subunit c of human ATP synthase[J]. Proc Natl Acad Sci U S A,2017,114(13):3409-3414.
    [6] BERNARDI P,RASOLA A,Forte M,et al. The mitochondrial permeability transition pore:Channel formation by F-ATP synthase,integration in signal transduction,and role in pathophysiology[J]. Physiological Reviews,2015,95(4):1111-1155.
    [7] RICCHELLI F,ŠILEIKYTE J,BERNARDI P. Shedding light on the mitochondrial permeability transition[J]. Biochimica Et Biophysica Acta,2011,1807(5):482-490.
    [8] DAS N,MANDALA A,NAAZ S,et al. Melatonin protects against lipid-induced mitochondrial dysfunction in hepatocytes and inhibits stellate cell activation during hepatic fibrosis in mice[J]. J Pineal Res,2017,62(4):e12404.
    [9] AKBARI G. Role of Zinc supplementation on ischemia/reperfusion injury in various organs[J]. Biol Trace Elem Res,2019.[Epub ahead of print]
    [10] MARD SA,AKBARI G,DIANAT M,et al. Protective effects of crocin and zinc sulfate on hepatic ischemia-reperfusion injury in rats:A comparative experimental model study[J]. Biomed Pharmacother,2017,96:48-55.
    [11] NARYZHNAYA NV,MASLOV LN,OELTGEN PR. Pharmacology of mitochondrial permeability transition pore inhibitors[J].Drug Dev Res,2019,80(8):1013-1030.
    [12] PANEL M,RUIZ I,BRILLET R,et al. Small-molecule inhibitors of cyclophilins block opening of the mitochondrial permeability transition pore and protect mice from hepatic ischemia/reperfusion injury[J]. Gastroenterology,2019,157(5):1368-1382.
    [13] SUN Y,SUKUMARAN P,SELVARAJ S,et al. TRPM2 promotes neurotoxin MPP+/MPTP-induced cell death[J]. Mol Neurobiol,2018,55(1):409-420.
    [14] FRIEDMAN JR,NUNNARI J. Mitochondrial form and function[J]. Nature,2014,505(7483):335-343.
    [15] CHEN X,YANG S,PAN Y,et al. Mitochondrial pathway-mediated apoptosis is associated with erlotinib-induced cytotoxicity in hepatic cells[J]. Oncology Letters,2018,15(1):783-788.
    [16] DAVE M,ATTUR M,PALMER G,et al. The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production[J]. Arthritis Rheum,2014,58(9):2786-2797.
    [17] FLORES-TORO JA,GO KL,LEEUWENBURGH C,et al. Autophagy in the liver:Cell's cannibalism and beyond[J]. Arch Pharm Res,2016,39(8):1050-1061.
    [18] BURKE PJ. Mitochondria,bioenergetics and apoptosis in cancer[J]. Trends Cancer,2017,3(12):857-870.
    [19] ZOU LY,ZHENG BY,FANG XF,et al. HBx co-localizes with COXIII in HL-7702 cells to upregulate mitochondrial function and ROS generation[J]. Oncology Reports,2015,33(5):2461-2467.
    [20] NASSIR F,IBDAH JA. Role of mitochondria in alcoholic liver disease[J]. World J Gastroenterol,2014,20(9):2136-2142.
    [21] LI J,WU DD,ZHANG JX,et al. Mitochondrial pathway mediated by reactive oxygen species involvement inα-hederininduced apoptosis in hepatocellular carcinoma cells[J].World J Gastroenterol,2018,24(17):1901-1910.
    [22] KRABBENDAM IE,HONRATH B,CULMSEE C,et al. Mitochondrial Ca2+-activated K+channels and their role in cell life and death pathways[J]. Cell Calcium,2018,69:101-111.
    [23] NURIA OV,SIMONA H,VORRINK SU,et al. Calcium signaling in liver injury and regeneration[J]. Front Med(Lausanne),2018,5:192.
    [24] ANTONY AN,PAILLARD M,MOFFAT C,et al. MICU1 regulation of mitochondrial Ca2+uptake dictates survival and tissue regeneration[J]. Nature Communications,2016,7:10955.
    [25] GUERRA MT,FONSECA EA,MELO FM,et al. Mitochondrial calcium regulates rat liver regeneration through the modulation of apoptosis[J]. Hepatology,2011,54(1):296-306.
    [26] CSORDÁS G,GOLENÁR T,SEIFERT EL,et al. MICU1 controls both the threshold and cooperative activation of the mitochondrial Ca2+uniporter[J]. Cell Metab,2013,17(6):976-987.
    [27] EMBADE N,MILLET O. Molecular determinants of chronic liver disease as studied by nmr-metabolomics[J]. Curr Top Med Chem,2017,17(24):2752.
    [28] SRINIVASAN S,GUHA M,KASHINA A,et al. Mitochondrial dysfunction and mitochondrial dynamics-The cancer connection[J]. Biochim Biophys Acta Bioenerg,2017,1858(8):602-614.
    [29] IOMMARINI L,GHELLI A,GASPARRE G,et al. Mitochondrial metabolism and energy sensing in tumor progression[J]. Biochim Biophys Acta Bioenerg,2017,1858(8):582-590.
    [30] MANSOURI A,GATTOLLIAT CH,ASSELAH T. Mitochondrial dysfunction and signaling in chronic liver diseases[J]. Gastroenterology,2018,155(3):629-647.
  • Relative Articles

    [1]Chinese Association of Integrative Medicine, Chinese Association of Integrative Medicine, Chinese Medical Association. Guidelines for integrated traditional Chinese and Western medicine diagnosis and treatment of liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(11): 2543-2549. doi: 10.3969/j.issn.1001-5256.2023.11.005
    [2]Chinese Association of Integrative Medicine, China Association of Chinese Medicine, Chinese Medical Association. Guidelines for the integrated traditional Chinese and Western medicine diagnosis and treatment of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(7): 1547-1552. doi: 10.3969/j.issn.1001-5256.2023.07.006
    [3]Shili JIANG, Ping LIU. Research advances in integrated traditional Chinese and Western medicine therapy for liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(9): 1953-1955. doi: 10.3969/j.issn.1001-5256.2022.09.001
    [4]Xianbo WANG, Ke SHI. Integrated traditional Chinese and Western medicine diagnosis and treatment of hepatic encephalopathy: Advances and perspectives[J]. Journal of Clinical Hepatology, 2022, 38(9): 1969-1973. doi: 10.3969/j.issn.1001-5256.2022.09.004
    [5]Changqing ZHAO. Integrated traditional Chinese and Western medicine diagnosis and treatment of liver cirrhosis with diabetes[J]. Journal of Clinical Hepatology, 2022, 38(9): 1980-1985. doi: 10.3969/j.issn.1001-5256.2022.09.006
    [6]Jiaqi LIANG, Wen LIU. Integrated traditional Chinese and Western medicine diagnosis and treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2022, 38(9): 1974-1979. doi: 10.3969/j.issn.1001-5256.2022.09.005
    [7]Lei WANG. Integrated traditional Chinese and Western medicine diagnosis and treatment of cirrhotic ascites[J]. Journal of Clinical Hepatology, 2022, 38(9): 1956-1961. doi: 10.3969/j.issn.1001-5256.2022.09.002
    [8]Chinese Association of Integrative Medicine. Expert consensus on the diagnosis and treatment of acute-on-chronic liver failure with integrated traditional Chinese and Western medicine[J]. Journal of Clinical Hepatology, 2021, 37(9): 2045-2053. doi: 10.3969/j.issn.1001-5256.2021.09.009
    [9]Wang XiaoJing, Liu Yao, Wang XianBo. Biochemical response and integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(1): 26-30. doi: 10.3969/j.issn.1001-5256.2020.01.004
    [10]Jiang ShiLi, Liu Ping. Current status and perspectives of integrated traditional Chinese and Western medicine therapy for hepatobiliary and pancreatic diseases[J]. Journal of Clinical Hepatology, 2020, 36(1): 10-13. doi: 10.3969/j.issn.1001-5256.2020.01.001
    [11]Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice (2019)[J]. Journal of Clinical Hepatology, 2019, 35(7): 1444-1449. doi: 10.3969/j.issn.1001-5256.2019.07.007
    [12]Liu Ping. A clinical analysis of strengthening integrated traditional Chinese and Western medicine therapy for prevention and treatment of liver cancer[J]. Journal of Clinical Hepatology, 2016, 32(4): 615-618. doi: 10.3969/j.issn.1001-5256.2016.04.001
    [13]Li Jun. Clinical research progress in integrated traditional Chinese and Western medicine therapy for HBV-related liver failure[J]. Journal of Clinical Hepatology, 2015, 31(1): 42-47. doi: 10.3969/j.issn.1001-5256.2015.01.010
    [14]Wang XianBo, Sun Le. Progress and prospect of diagnosis and treatment of hepatic fibrosis by integrated traditional Chinese and Western medicine therapy[J]. Journal of Clinical Hepatology, 2015, 31(1): 38-41. doi: 10.3969/j.issn.1001-5256.2015.01.009
    [15]Wei BeiHai, Zhou Tao. Current and future perspectives on integrative traditional Chinese and Western medical management of gastroenterological diseases[J]. Journal of Clinical Hepatology, 2013, 29(4): 241-244.
    [16]Liu ChengHai, Xing Feng. The potential benefit managing ascites due to cirrhosis using an integrative medicine approach[J]. Journal of Clinical Hepatology, 2013, 29(4): 253-256.
    [17]Yao XiXian, Yao DongMei. Combination treatment of Chinese traditional and Western medicine in chronic hepatitis and liver fibrosis[J]. Journal of Clinical Hepatology, 2013, 29(4): 245-248+252.
    [18]Zhou ShuangNan, Wang LiFu, Yang HuiYin, Bai YunFeng, Li Yun. Analysis of clinical effects and prognosis of patients with early-mid stage chronic severe hepatitis B treated with integrated traditional and western medicine[J]. Journal of Clinical Hepatology, 2011, 27(5): 471-473.
    [19]Tang ZhaoYou. Combination of traditional Chinese medicine and western medicine in the treatment of liver cancer[J]. Journal of Clinical Hepatology, 2011, 27(5): 449-450.
    [20]Li YouTian, Li Yang, Li Bing. Effect of combination of traditional chinese medicine and western medicine on ascites resulted from liver cirrhosis[J]. Journal of Clinical Hepatology, 2003, 19(3): 150-151.
  • Cited by

    Periodical cited type(16)

    1. 巴明玉,潘研,王娴,陈亚琳,燕树勋. 强肝胶囊对非酒精性脂肪肝肥胖患者糖脂代谢水平及肝功能的影响. 中医学报. 2024(02): 416-420 .
    2. 范文,郑垂仰,周旋,孔怡琳,潘丰满,杨钦河,张玉佩. 6种中成药治疗非酒精性脂肪性肝病有效性和安全性的网状Meta分析. 中药新药与临床药理. 2023(11): 1612-1622 .
    3. 崔姗姗,刘英,江霞. 非酒精性脂肪性肝病与胰岛素抵抗的研究进展. 医学信息. 2022(10): 66-69 .
    4. 舒祥兵,操颖,顾晔,杨志新,季光,张莉. 强肝胶囊促进肝糖原合成降低大鼠高血糖的机制研究. 上海中医药大学学报. 2021(03): 45-51 .
    5. 贾英杰,张晓博,张新元,杨红霞,郭争荣. 强肝胶囊对猪血清诱导大鼠肝纤维化的治疗作用. 河北医药. 2021(20): 3104-3107 .
    6. 朱丹,孙婷婷,陈兰羽,谢铮. 脂肪性肝病中医药认识. 辽宁中医药大学学报. 2020(05): 70-73 .
    7. 崔翔,刘玲兰,华鹏,郭薇,薛敬东. 从脾论治非酒精性脂肪性肝病的体会与研究概况. 中医临床研究. 2020(14): 136-138 .
    8. 郭明升,刘娟,郭英杰,籍芳华,郝艳爽. 阿托伐他汀联用脂康颗粒或强肝胶囊用于脑梗死二级预防效果比较. 现代中西医结合杂志. 2020(22): 2400-2404+2446 .
    9. 王秀琴. 强肝胶囊联合甘草酸二铵肠溶胶囊治疗非酒精性脂肪肝的效果. 河南医学研究. 2019(06): 1089-1091 .
    10. 黄静,陈湘清,郭东升,吴奋. 同步抗感染治疗对合并幽门螺杆菌感染非酒精性脂肪肝病患者治疗结局的影响研究. 重庆医学. 2018(01): 97-100 .
    11. 陈少颖,易新宇,周小博,张荣臻. 中医药治疗非酒精性脂肪肝的研究进展. 大众科技. 2018(06): 68-70 .
    12. 周桃梅,杨上文,汪剑波. 强肝胶囊联合二甲双胍治疗非酒精性脂肪肝的疗效及其对Nod样受体-3炎症小体的影响. 中国医院统计. 2018(03): 206-208 .
    13. 柳琳琳,毛德文,吕建林,黄瑞. 强肝胶囊对非酒精性脂肪性肝病患者疗效及安全性的Meta分析. 中成药. 2018(08): 1715-1720 .
    14. 李滨,张佳圆,王凤永,李春晖,齐丽韫,王玉华,赵培利. 胆宁片治疗非酒精性脂肪肝临床效果及对血脂、肝功能和肝纤维化的影响. 解放军医药杂志. 2018(10): 93-96 .
    15. 朱紫馨,祝丽丽,程明亮. 同步抗感染治疗非酒精性脂肪肝合并幽门螺杆菌感染的效果观察. 临床合理用药杂志. 2018(31): 58-59 .
    16. 李军祥,王允亮,郭一,谢添弘. 中医药治疗非酒精性脂肪性肝病专题笔谈. 中国中西医结合消化杂志. 2017(11): 801-804 .

    Other cited types(13)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 6.6 %FULLTEXT: 6.6 %META: 86.8 %META: 86.8 %PDF: 6.6 %PDF: 6.6 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.0 %其他: 7.0 %China: 0.4 %China: 0.4 %Rochester: 0.6 %Rochester: 0.6 %United States: 0.2 %United States: 0.2 %[]: 0.2 %[]: 0.2 %上海: 2.3 %上海: 2.3 %东京: 0.4 %东京: 0.4 %北京: 5.1 %北京: 5.1 %南京: 0.4 %南京: 0.4 %南宁: 0.2 %南宁: 0.2 %台湾省: 0.4 %台湾省: 0.4 %吉林: 0.9 %吉林: 0.9 %大理白族自治州: 0.2 %大理白族自治州: 0.2 %天津: 0.2 %天津: 0.2 %广州: 0.2 %广州: 0.2 %张家口: 2.6 %张家口: 2.6 %杭州: 0.6 %杭州: 0.6 %武汉: 1.1 %武汉: 1.1 %湛江: 0.2 %湛江: 0.2 %石家庄: 0.4 %石家庄: 0.4 %秦皇岛: 0.2 %秦皇岛: 0.2 %艾因: 0.6 %艾因: 0.6 %芒廷维尤: 33.9 %芒廷维尤: 33.9 %芝加哥: 0.2 %芝加哥: 0.2 %苏州: 0.4 %苏州: 0.4 %莫斯科: 1.1 %莫斯科: 1.1 %西宁: 36.0 %西宁: 36.0 %诺沃克: 0.2 %诺沃克: 0.2 %运城: 0.2 %运城: 0.2 %重庆: 0.9 %重庆: 0.9 %镇江: 0.2 %镇江: 0.2 %长春: 0.4 %长春: 0.4 %长沙: 0.2 %长沙: 0.2 %长治: 0.2 %长治: 0.2 %马哈拉施特拉邦: 1.3 %马哈拉施特拉邦: 1.3 %其他ChinaRochesterUnited States[]上海东京北京南京南宁台湾省吉林大理白族自治州天津广州张家口杭州武汉湛江石家庄秦皇岛艾因芒廷维尤芝加哥苏州莫斯科西宁诺沃克运城重庆镇江长春长沙长治马哈拉施特拉邦

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1831) PDF downloads(340) Cited by(29)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return